MagVenture Receives FDA Clearance to Expand TMS Therapy Indication for Adolescents Aged 15–21

ALPHARETTA, GA, UNITED STATES, August 25, 2025 /EINPresswire.com/ -- MagVenture, the global leader of non-invasive TMS neuromodulation technology, announced today that the U.S. Food and Drug Administration (FDA) has granted clearance for an expanded indication of its MagVenture TMS Therapy^® system. The system is now indicated as an adjunct treatment for Major Depressive Disorder (MDD) in adolescent patients aged 15 to 21 who have not responded adequately to prior antidepressant medication.

This clearance allows U.S.-based providers using MagVenture systems to now offer this safe, effective, and non-pharmacological therapy to adolescent patients, supporting a growing clinical demand for alternative depression treatments in younger populations.

Up to 20% of adolescents will have a major depressive episode before adulthood, meaning that the mental health needs of this demographic are both urgent and complex. Many teens face barriers to sustained medication use, with non-compliance rates up to 60%, making alternative treatment options increasingly relevant.

MagVenture TMS Therapy utilizes magnetic pulses generated by MagVenture’s liquid-cooled treatment coils to stimulate neurons in areas of the brain associated with depression, including the left dorsolateral prefrontal cortex (DLPFC). This region is closely linked with mood regulation. TMS is a noninvasive procedure and does not require anesthesia or systemic medication. Each session typically lasts about 20 minutes and can be seamlessly integrated into a patient’s weekly schedule without the need for recovery time.

For adolescent patients, the clinical promise of TMS is significant. Treatment benefits may last up to six months, offering patients and their families a meaningful window of symptom relief and recovery.

Payers continue to expand coverage of TMS for adolescent patients aged 15-21 with Major Depressive Disorder (MDD). It is covered by many major insurers, including Humana, Aetna, Cigna (Evernorth), Health Care Service Corporation, BlueCross BlueShield of North Carolina, BlueCross BlueShield of Michigan, and some state Medicaid programs, including California Medi-Cal.

Martha Koo, M.D., Chief Medical Officer of Your Behavioral Health and Neuro Wellness Spa and immediate past President of the Clinical TMS Society, commented, “Many of our adolescent patients arrive feeling hopeless- believing they’ve exhausted treatment options and will never again enjoy friends, hobbies, or school. With MagVenture TMS Therapy, we’ve been able to offer a noninvasive approach that resonates with teens and their families and gets results. We’ve observed sustained improvements in mood and function, especially in those who were previously medication non-compliant.” Dr. Koo will lead an educational webinar on September 17th, 2025, at 8:00 am Pacific Time/11:00 am Eastern Time for providers to learn more about using TMS to treat younger patients with depression. Registration information can be found here.

TMS therapy is considered safe and effective for adolescent use, with the most commonly reported side effect being temporary discomfort at or near the treatment site, usually occurring early in the treatment course. Overall, MagVenture TMS Therapy has demonstrated a favorable safety profile and offers a viable adjunctive treatment for adolescents with MDD who may not benefit from or cannot tolerate pharmacologic therapies alone.

MagVenture has also recently cleared the T65 coil that be used for treatment of MDD. T65 coil—MagVenture’s lightest cooled coil—combines the functionality of the C-B60 and Cool-B65 into a single solution for both motor threshold measurement and treatment. With a lighter-weight, quieter performance, quick-connect design, and longer lifetime, the T65 is engineered to reduce operator fatigue, improve the patient experience, and increase workflow efficiency while maintaining the proven magnetic field properties of the Cool-B65.

Kerry Rome, Senior Vice President of MagVenture Inc., noted that these regulatory milestones reinforce the company’s broader commitment to innovation and access. “This expanded FDA indication and introduction of the T65 coil advance our mission to make effective, non-invasive treatment accessible to more patients. We strive to support clinicians with technologies that are grounded in evidence, adaptable in practice, and driven by real patient needs.”
MagVenture’s TMS systems are widely used across academic institutions, private clinics, and hospital networks, with a reputation for precision engineering, flexible protocols, and integrated safety features. The addition of the adolescent indication enables current and new MagVenture customers to meet the needs of a growing patient group with confidence and continuity of care.

About MagVenture
MagVenture develops and manufactures non-invasive magnetic stimulation systems used globally in psychiatry, neurophysiology, neurology, cognitive neuroscience, rehabilitation, and pain management. With over three decades of experience in the field, the company is committed to delivering safe, effective, and future-facing treatment technologies that empower healthcare professionals and support better outcomes for patients of all ages.

More Information
Kerry Rome
Senior Vice President, MagVenture Inc.
+1 888 624 7764
kr@magventure.com
www.magventure.com

Kerry Rome
MagVenture, Inc.
+1 888-624-7764
kr@magventure.com
Visit us on social media:
LinkedIn
Instagram
YouTube

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.